Can we develop neurally acting drugs for the treatment of migraine?

Nature Reviews Drug Discovery

Volumn 4, Issue 9, 2005, Pages 741-750

  Goadsby, Peter J ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; ADENOSINE A1 RECEPTOR AGONIST; ANTIMIGRAINE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; FLUNARIZINE; GABAPENTIN; GLUTAMATE RECEPTOR ANTAGONIST; GLYCERYL TRINITRATE; GR 190178; IONOTROPIC RECEPTOR ANTAGONIST; KETAMINE; METHYSERGIDE; OLCEGEPANT; PNU 142633; PROPRANOLOL; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SEROTONIN 1F AGONIST; SEROTONIN AGONIST; SILDENAFIL; SUMATRIPTAN; TONABERSAT; TOPIRAMATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VANILLOID RECEPTOR;

BRAIN DISEASE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTINGENT NEGATIVE VARIATION; CORONARY ARTERY CONSTRICTION; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG TARGETING; HUMAN; MIGRAINE; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SPREADING CORTICAL DEPRESSION; THORAX PAIN; VASOCONSTRICTION; CARDIOVASCULAR FUNCTION; DRUG DELIVERY SYSTEM; DRUG EFFECT; METHODOLOGY;

CARDIOVASCULAR PHYSIOLOGY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; MIGRAINE DISORDERS;

EID: 26044477297     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1822     Document Type: Review

References (224)

1. Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L. & Reed, M. Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 41, 646-657 (2001).
2. Menken, M., Munsat, T. L. & Toole, J. F. The global burden of disease study: Implications for neurology. Arch. Neurol. 57, 418-420 (2000).
3. Goadsby, P. J., Lipton, R. B. & Ferrari, M. D. Migraine: Current understanding and treatment. N. Engl. J. Med. 346, 257-270 (2002).
4. Lance, J. W. & Goadsby, P. J. Mechanism and Management of Headache (Elsevier, New York, 2005).
5. Goadsby, P. J. The pharmacology of headache. Prog. Neurobiol. 62, 509-525 (2000).
6. Doenicke, A., Siegel, E., Hadoke, M. & Perrin, V. L. Initial clinical study of AH25086B (5-HT,-like agooist) in the acute treatment of migraine. Cephalalgia 7, 437-438 (1987).
7. Doenicke, A., Brand, J. & Perrin, V. L. Possible benefit of GR43175, a novel 5-HT,-like receptor agonist,, for the acute treatment of severe migraine. Lancet 1, 1309-1311 (1988).
8. Ferrari, M. D. & The Subcutaneous Sumatriptan International Study Group. Treatment of migraine attacks with sumatriptan. N. Engl. J. Med. 325, 316-321 (1991).
9. 1B/1D agonists) in the acute treatment of migraine. Headache 44, 414-425 (2004).
10. 1B/1D agonists) in acute migraine treatment: A meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001).
11. 1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 22, 633-658 (2002).
12. Goadsby, P. J. Post-triptan era for the treatment of acute migraine. Curr. Pain Headache Rep. 8, 393-398 (2004).
13. Cohen, A. S. & Goadsby, P. J. Functional neuroimaging of primary headache disorders. Curr. Neurol. Neurosci. Rep. 4, 105-110 (2004).
14. Hadjikhani, N. et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl Acad. Sci. USA 98, 4687-4692 (2001).
15. Kaube, H. & Giffin, N. J. The electrophysiology of migraine. Curr. Opin. Neurol. 15, 303-309 (2002).
16. Ambrosini, A. & Schoenen, J. The electrophysiology of migraine. Curr. Opin. Neurol. 16, 327-331 (2003).
17. Weiller, C. et al. Brain stem activation in spontaneous human migraine attacks. Nature Med. 1, 658-660 (1995).
18. Welch, K. M., Nagesh, V., Aurora, S. & Gelman, N. Periaqueductal grey matter dysfunction in migraine: Cause or the burden of illness? Headache 41, 629-637 (2001).
19. Goadsby, P. J. Neurovascular headache and a midbrain vascular malformation: Evidence for a role of the brainstem in chronic migraine. Cephalalgia 22, 107-111 (2002).
20. Haas, D. C., Kent, P. F. & Friedman, D. I. Headache caused by a single lesion of multiple sclerosis in the periaqueductal gray area. Headache 33, 452-455 (1993).
21. Raskin, N. H., Hosobuchi, Y. & Lamb, S. Headache may arise from perturbation of brain. Headache 27, 416-420 (1987).
22. Veloso, F., Kumar, K. & Toth C. Headache secondary to deep brain implantation. Headache 38, 507-515 (1998).
23. Knight, Y. E. & Goadsby, P. J. The periaqueductal gray matter modulates trigeminovascular input: A role in migraine? Neuroscience 106, 793-800 (2001).
24. Knight, Y. E., Bartsch, T. & Goadsby, P. J. Trigeminal antinociception induced by bicuculline in the periaqueductal grey (PAG) is not affected by PAG P/Q-type calcium channel blockade in rat. Neurosci. Lett. 336, 113-116 (2003).
25. Knight, Y. E., Bartsch, T., Kaube, H. & Goadsby, P. J. P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: A functional genetic link for migraine? J. Neurosci. 22, 1-6 (2002).
26. Bandler, R. & Keay, K. A. Columnar organization in the midbrain periaqueductal gray and the integration of emotional expression. Progress Brain Res. 107, 285-300 (1996).
27. 1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann. Neurol. 56, 371-381 (2004).
28. Afridi, S. & Goadsby, P. J. New onset migraine with a brainstem cavernous angioma. J. Neurol. Neurosurg. Psychiatr. 74, 680-682 (2003)
29. Bahra, A., Matharu, M. S., Buchel, C., Frackowiak, R. S. J. & Goadsby, P. J. Brainstem activation specific to migraine headache. Lancet 357, 1016-1017 (2001).
30. Afridi, S. et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Cephalalgia 24, 775-776 (2004).
31. Afridi, S. et al. A PET study in spontaneous migraine. Arch. Neurol. 62, 1270-1275 (2005).
32. Amaral, D. G. & Sinnamon, H. M. The locus coeruleus: Neurobiology of a central noradrenergic nucleus. Prog. Neurobiol. 9, 147-196 (1977).
33. Goadsby, P. J., Lambert, G. A. & Lance, J. W. Differential effects on the internal and external carotid circulation of the monkey evoked by locus coeruleus stimulation. Brain Res. 249, 247-254 (1982).
34. Goadsby, P. J. & Duckworth, J. W. Low frequency stimulation of the locus coeruleus reduces regional cerebral blood flow in the spinalized cat. Brain Res. 476, 71-77 (1989).
35. May, A., Bahra, A., Buchel, C., Frackowiak, R. S. J. & Goadsby, P. J. Hypothalamic activation in cluster headache attacks. Lancet 352, 275-278 (1998).
36. May, A. et al. Experimental cranial pain elicited by capsaicin: A PET-study. Pain 74, 61-66 (1998).
37. Tracey, I. et al. Imaging attentional modulation of pain in the periaqueductal gray in humans. J. Neurosci. 22, 2748-2752 (2002).
38. Schoenen, J., Ambrosini, A., Sandor, P. S. & Maetens de Noordhout, A. Evoked potentials and transcranial magnetic stimulation in migraine: published data and viewpoint on their pathophysiologic significance. Clin. Neurophysiol. 114, 955-972 (2003).
39. Afra, J., Sandor, P. & Schoenen, J. Habituation of visual and intensity dependence of cortical auditory evoked potentials tend to normalise just before and during migraine attacks. Cephalalgia 20, 347 (2000).
40. 1B/1D agonist zolmitriptan (311C90, Zomig). Cephalalgia 17, 849-854 (1997).
41. Schoenen, J., Wang, W., Albert, A. & Delwaide, P. J. Potentiation instead of habituation characterizes visual evoked potentials in migraine patients between attacks. Eur. J. Neurol. 2, 115-122 (1995).
42. Wang, W. & Schoenen, J. Interictal potentiation of passive 'oddball' auditory event-related potentials in migraine. Cephalalgia 18, 261-265 (1998).
43. Niebur, E., Hsiao, S. S. & Johnson, K. O. Synchrony: A neural mechanism for attentional selection? Curr. Opin. Neurobiol. 12, 190-194 (2002).
44. Angelini, L. et al. Steady-state visual evoked potentials and phase synchronization in migraine patients. Phys. Rev. Lett. 93, 038103-1-038103-4 (2004).
45. Goadsby, P. J. Migraine pathophysiology: The brainstem governs the cortex. Cephalalgia 23, 565-566 (2003).
46. Schoenen, J. & Timsit-Berthier, M. Contingent negative variation: methods and potential interest in headache. Cephalalgia 13, 28-32 (1993).
47. Kropp, P. & Gerber, W. D. Prediction of migraine attacks using a slow cortical potential, the contingent negative variation. Neurosci. Lett, 257, 73-76 (1998).
48. Maertens de Noordhout, A., Timsit-Berthier, M. & Schoenen, J. Contingent negative variation (CNV) in migraineurs before and during prophylactic treatment with β-blockers. Cephalalgia 5, 34-35 (1985).
49. Gantenbein, A., Goadsby, P. J. & Kaube, H. Introduction of a clinical scoring system for migraine research applied to electrophysiological studies. Cephalalgia 24, 1095-1096 (2004).
50. Headache Classification Committee of The International Headache Society. The International Classification of Headache Disorders (second edition). Cephalalgia 24, 1-160 (2004).
51. Olesen, J. et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol 28, 791-798 (1990).
52. Cutrer, F. M. et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann. Neurol. 43, 25-31 (1998).
53. Leao, A. A. P. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359-390 (1944).
54. Leao, A. A. P. Pial circulation and spreading activity in the cerebral cortex. J. Neurophysiol. 7, 391-396 (1944).
55. Lauritzen, M. Pathophysiology of the migraine aura. The spreading depression theory. Brain 117, 199-210 (1994).
56. Moskowitz, M. A., Bolay, H. & Dalkara, T. Deciphering migraine mechanisms: Clues from familial hemiplegic migraine genotypes. Ann. Neurol. 55, 276-280 (2004).
57. Goadsby, P. J. Migraine, aura and cortical spreading depression: Why are we still talking about it? Ann. Neurol. 49, 4-6 (2001).
58. De Vries, P., Villalon, C. M. & Saxena, P. R. Pharmacological aspects of experimental headache models in relation to acute antimigraine therapy. Eur. J. Pharmacol. 375, 61-74 (1999).
59. Goadsby, P. J. & Kaube, H. in The Headaches 2nd edn (eds Olesen, J., Tfelt-Hansen, P. & Welch, K. M. A.) 195-202 (Lippincott Williams & Wilkins, Philadelphia, 2000).
60. Saxena, P. R. & De Boer, M. O. Pharmacology of antimigraine drugs. J. Neurol. 238, S28-S35 (1991).
61. Saxena, P. R. & Cairo-Rawlins, W. I. Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. Eur. J. Pharmacol. 58, 305-312 (1979).
62. Markowitz, S., Saito, K. & Moskowitz, M. A. Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J. Neurosci. 7, 4129-4136 (1987).
63. Markowitz, S., Saito, K. & Moskowitz, M. A. Neurogenically mediated plasma extravasation in dura mater: Effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 8, 83-91 (1988).
64. Williamson, D. J., Hargreaves, R. J., Hill, R. G. & Shepheard, S. L. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat- intravital microscope studies. Cephalalgia 17. 525-531 (1997).
65. Kaube, H., Hoskin, K. L. & Goadsby, P. J. Activation of the trigeminovascular system by mechanical distension of the superior sagittal sinus in the cat. Cephalalgia 12, 133-136 (1992).
66. Burstein, R. & Jakubowski, M. Analgesic triptan action in an animal model of intracranial pain: A race against the development of central sensitisation. Ann. Neurol. 55, 27-36 (2004).
67. Selby, G. & Lance, J. W. Observations on 500 cases of migraine and allied vascular headache. J. Neurol. Neurosurg. Psychiatr. 23, 23-32 (1960).
68. Tfelt-Hansen, P. et al. Ergotamine in the acute treatment of migraine: A review and European consensus. Brain 123, 9-18 (2000).
69. 1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 11, 165-168 (1991).
70. Hoskin, K. L., Kaube, H. & Goadsby, P. J. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine. A c-Fos and electrophysiology study. Brain 119, 249-256 (1996).
71. Read, S. J., Smith, M. I., Hunter, A. J., Upton, N. & Parsons, A. A. SB-220453, a potential novel antimigraine compound, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 20, 92-99 (1999).
72. Smith, M. I. et al. Repetitive cortical spreading depression in a gyrencephalic feline brain: Inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia 20, 546-53 (2000).
73. MaassenVanDenBrink, A. et al. The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia 20, 538-545 (2000).
74. Parsons, A. A. et al. Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br. J. Pharmacol. 132, 1549-1557 (2001).
75. Diener, H. C. et al. Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J. Neurol. 251, 943-950 (2004).
76. Brandes, J. L. et al. Topiramate for migraine prevention: A randomized controlled trial. JAMA 291, 965-973 (2004).
77. Silberstein, S. D., Neto, W., Schmitt, J. & Jacobs, D. Topiramate in migraine prevention: Results of a large controlled trial. Arch. Neurol. 61, 490-495 (2004).
78. Akerman, S. & Goadsby, P. J. Topiramate inhibits cortical spreading depression in rat and cat: A possible contribution to its preventive effect in migraine. Cephalalgia 24, 783-784 (2004).
79. Tvedskov, J. F., Iversen, H. K. & Olesen, J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia 24, 875-882 (2004).
80. Tvedskov, J. F. et al. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia 24, 1076-1087 (2004).
81. Tvedskov, J. F. et al. The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia 24, 576-585 (2004).
82. Storer, R. J. & Goadsby, P. J. Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia 24, 1049-1056 (2004).
83. 2+ channel gene CACNL1A4. Cell 87, 543-552 (1996).
84. van den Maagdenberg, A. M. J. M. et al. A Cacna1a knock-in migraine mouse: Model with increased susceptibility to cortical spreading depression. Neuron 41, 701-710 (2004).
85. Shank, R. P., Gardocki, J. F., Streeter A. J. & Maryanoff, B. E. An overview of the preclinical aspects of topiramate: Pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 41, S3-S9 (2000).
86. 2+ channel blockers lidoflazine and flunarizine. Neurosci. Lett. 158, 97-100 (1993).
87. Ebersberger, A., Portz, S., Meissner, W., Schaible, H. G. & Richter, F. Effects of N-, P/Q- and L-type calcium channel blockers on nociceptive neurones of the trigeminal nucleus with input from the dura. Cephalalgia 24, 250-261 (2004).
88. Shields, K. G., Storer, R. J., Akerman, S. & Goadsby, P. J. Calcium channels modulate nociceptive transmission in the trigeminal nucleus of the cat. Neuroscience (in the press).
89. Akerman, S., Williamson, D. & Goadsby, P. J. Voltage-dependent calcium channels are involved in neurogenic dural vasodilation via a pre-synaptic transmitter release mechanism. Br. J. Pharmacol. 140, 558-566 (2003).
90. Kimball, R. W., Friedman, A. P. & Vallejo, E. Effect of serotonin in migraine patients. Neurology 10, 107-111 (1960).
91. Lance, J. W., Anthony, M. & Hinterberger, H. The control of cranial arteries by humoral mechanisms and its relation to the migraine syndrome. Headache 7, 93-102 (1967).
92. Humphrey, P. P. A. et al. Serotonin and migraine. Ann. NY Acad. Sci. 600, 587-598 (1990).
93. Lance, J. W., Fine, R. D. & Curran, D. A. An evaluation of methysergide in the prevention of migraine and other vascular headache. Med. J. Aust. 1, 814-818 (1963).
94. Johnson, B. M. & Saxena, P. R. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br. J. Pharmacol. 63, 541-549 (1978).
95. 1F receptors-binding affinities, brain penetration and activity in the neurogenic dural inflammation model o. migraine. Life Sci. 61, 2117-2126 (1997).
96. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs. NeuroReport 8, 2237-2240 (1997).
97. Cohen, M. L. & Schenck, K. 5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: Lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein. J. Pharmacol. Exp. Ther. 290, 935-939 (1999).
98. 1F-receptor activation. Br. J. Clin. Pharmacol. 47, 75-82. (1999).
99. Goldstein, D. J. et al. Selective serotonin 1F (5-HT(1F)). receptor agonist LY334370 for acute migraine: A randomised controlled trial. Lancet 358, 1230-1234 (2001).
100. 1F receptors) in human brain: Focus on brainstem and spinal cord. Neuropharmacology 36, 535-542 (1997)
101. 1F receptors. Eur. J. Pharmacol. 295, 271-274 (1996).
102. 1F receptor bindings sites in the guinea pig brain: An autoradiographic study. Naunyn Schmiedebergs Arch. Pharmacol. 352, 263-275 (1995).
103. 1F binding sites in rat brain: Effect of serotonergic lesioning. J. Recept. Sig. Transduct. Res. 17, 631-645 (1997).
104. Bouchelet, I., Cohen, Z., Case, B. & Hamel, E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol. Pharmacol. 50, 219-223 (1996).
105. 1F receptors modulate c-fos expression within rat trigeminal nucleus caudalis. Eur. J. Pharmacol. 359, 271-277 (1999).
106. 1F receptor inhibitory effects on trigeminal neurons with craniovascular input. Neuroscience 122, 491-498 (2003).
107. 1F receptor immunoreactivity (IR) in the rat trigeminocervical complex (TCC) new therapeutic possibilities for the triptans. Cephalalgia 24, 148 (2004).
108. McCall, R. B. et al. Preclinical studies characterizing the anti-migraine and cardiovascular effects of the selective 5-HT 1D receptor agonist PNU-142633. Cephalalgia 22, 799-806 (2002).
109. McCall, R. B. Trigeminal ganglion elicited increases in nucleus trigeminal caudalis blood flow: A novel migraine model. Brain Res. 775, 189-192 (1997).
110. 1D receptor agonist U-109291 blocks dural plasma extravasation and c-fos expression in the trigeminal nucleus caudalis. Cephalalgia 17, 401 (1997).
111. Potrebic, S., Ahan, A. H., Skinner, K., Fields, H. L. & Basbaum, A. I. Peptidergic nociceptors of both trigeminal and dorsal root ganglia express serotonin 1D receptors: Implications for the selective antimigraine action of triptans. J. Neurosci. 23, 10988-10997 (2003).
112. 1D is dynamically regulated in the central terminal of primary afferents in models of pain. Neurology 62, A440-A441 (2004).
113. 1D receptors cloned from chimpanzee, gorilla and rhesus monkey in comparison with those from the human and guinea pig receptors. Neurosci. Lett. 235, 117-120 (1997).
114. 1D agonist, in patients with acute migraine. Cephalalgia 21, 727-732 (2001).
115. 1D-selective ligands). Br. J. Pharmacol. 127, 468-472 (1999).
116. 1D agonist, PNU- 142633F. Int. J. Clin. Pharmacol. Ther. 37, 487-492 (1999).
117. Clements, J. R., Magnusson, K. R., Hautman, J. & Beitz, A. J. Rat tooth pulp projections to spinal trigeminal subnucleus caudalis are glutamate-like immunoreactive. J. Comp. Neurol. 309, 281-288 (1991).
118. Magnusson, K. R., Larson, A. A., Madl, J. E., Altschuler, R. A. & Beitz, A. J. Co-localization of fixative-modified glutamate and glutaminase in neurons of the spinal trigeminal nucleus of the rat: An immunohistochemical and immunoradiochemical analysis. J. Comp. Neurol. 247, 477-490 (1986).
119. Tallaksen-Greene, S. J., Young, A. B., Penney, J. B. & Beitz, A. J. Excitatory amino acid binding sites in the trigeminal principal sensory and spinal trigeminal nuclei of the rat. Neurosci. Lett. 141, 79-83 (1992).
120. Storer, R. J. & Goadsby, P. J. Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 90, 1371-1376 (1999).
121. Goadsby, P. J. & Classey, J. D. Glutamatergic transmission in the trigeminal nucleus assessed with local blood flow. Brain Res. 875, 119-124 (2000).
122. Classey, J. D., Knight, Y. E. & Goadsby, P. J. The NMDA receptor antagonist MK-801 reduces Fos-like immunoreactivity within the trigeminocervical complex following superior sagittal sinus stimulation in the cat. Brain Res. 907, 117-124 (2001).
123. Mitsikostas, D. D., Sanchez del Rio, M., Waeber, G., Moskowitz, M. A. & Cutrer, F. M. The NMDA receptor antagonist MK-801 reduces capsaicin-induced c-fos expression within rat trigeminal nucleus caudalis. Pain 76, 239-248 (1998).
124. Mitsikostas, D. D. et al. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br. J. Pharmacol. 127, 623-630 (1999).
125. Shields, K. G., Kaube, H. & Goadsby, P. J. GABA receptors modulate trigeminovascular nociceptive transmission in the ventroposteromedial (VPM) thalamic nucleus of the rat. Cephalalgia 23, 728 (2003).
126. Shields, K. G. & Goadsby, P. J. Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: A role in migraine? Brain 128, 86-97 (2005).
127. Ramadan, N. M. et al. IV LY293558, an AMPA/kainate receptor antagonist, is effective in migraine. Cephalalgia 21, 267-268 (2001).
128. Kaube, H., Herzog, J., Kaufer, T., Dichgans, M. & Diener, H. C. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 55, 139-141 (2000).
129. Edvinsson, L., Ekman, R., Jansen, I., McCulloch, J. & Uddman, R. Calcitonin gene-related peptide and cerebral blood vessels: Distribution and vasomotor effects. J. Cereb. Blood Flow Metab. 7, 720-728 (1987).
130. Goadsby, P. J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann. Neurol. 23, 193-196 (1988).
131. Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183-187 (1990).
132. Gallai, V. et al. Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15, 384-390 (1995).
133. Goadsby, P. J. & Edvinsson, L. Human in vivo evidence for trigeminovascular activation in cluster headache. Brain 117, 427-434 (1994).
134. Fanciullacci, M., Alessandri, M., Figini, M., Geppetti, P. & Michelacci, S. Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain 60, 119-123 (1995).
135. Thomsen, L. L., Kruuse, C., Iversen, H. K. & Olesen, J. A nitric oxide donor (nitroglycerine) triggers genuine migraine attacks. Eur. J. Neurol. 1, 73-80 (1994).
136. Afridi, S., Kaube, H. & Goadsby, P. J. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 110, 675-680 (2004).
137. Juhasz, G. et al. NO-induced migraine attack: Strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain 106, 461-470 (2003).
138. Buzzi, M. G., Moskowitz, M. A., Shimizu, T. & Heath, H. H. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 30, 1193-1200 (1991).
139. Arvieu, L. et al. Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord. Neuroreport 7, 1973-1976 (1996).
140. Goadsby, P. J. & Edvinsson, L. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache 34, 394-399 (1994).
141. Goadsby, P. J. & Edvinsson, L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. 33, 48-56 (1993).
142. Zagami, A. S., Goadsby, P. J. & Edvinsson, L. Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides 16, 69-75 (1990).
143. Knight, Y. E., Edvinsson, L. & Goadsby, P. J. Blockade of CGRP release after superior sagittal sinus stimulation in cat: A comparison of avitriptan and CP122, 288. Neuropeptides 33, 41-46 (1999).
144. 1B/1D receptor agonist activity. Neuropharmacology 40 520-525 (2001).
145. Durham, P. L., Sharma, R. V. & Russo, A. F. Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J. Neurosci. 17, 9545-9553 (1997).
146. Durham, P. L. & Russo, A. F. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J. Neurosci. 19, 3423-3429 (1999).
147. Doods, H. et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. 129, 420-423 (2000).
148. Moreno, M. J. Abounader, R., Hebert, E., Doods, H. & Hamel, E. Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: Potential implications in acute migraine treatment. Neuropharmacology 42, 568-576 (2002).
149. Petersen, K. A., Lassen, L. H., Birk, S. & Olesen, J. The effect of the nonpeptide CGRP-antagonist, BIBN406BS on human-αCGRP induced headache and hemodynamics in healthy volunteers. Cephalalgia 23, 725 (2003).
150. Storer, R. J., Akerman, S. & Goadsby, P. J. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol. 142, 1171-1181 (2004).
151. Olesen, J. et al. Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS is effective in the treatment of migraine attacks. New Eng. J. Med. 350, 1104-1110 (2004).
152. Petersen, K. A. et al. The novel CGRP-antagonist, BIBN4096BS does not affect the cerebral hemodynamics in healthy volunteers. Cephalalgia 23, 729 (2003).
153. Sawynok, J. Adenosine receptor activation and nociception. Eur. J. Pharmacol. 347, 1-11 (1998).
154. Sawynok, J. Purines in pain management. Curr. Opin. Cent. Peripher. Nerv. Syst. Investig. Drugs 1, 27-38 (1999).
155. Paalzow, G. & Paalzow, L. The effects of caffeine and theophylline on nociceptive stimulation in the rat. Acta Pharmacol. Toxicol. 32, 22-32 (1973).
156. Sawynok, J., Sweeney, M. I. & White, T. D. Classification of adenosine receptors mediating antinociception in the rat spinal cord. Br. J. Pharmacol. 88, 923-930 (1986).
157. Sjolund, K.-F., Sollevi, A., Segerdahl, M., Hansson, P. & Lundeberg, T. Intrathecal and systemic R-phenylisopropy-adenosine reduces scratching behaviour in a rat mononeuropathy model. NeuroReport 7, 1856-1860 (1996).
158. DeLander, G. E. & Hopkins, G. J. Spinal adenosine modulates descending antinociceptive pathways stimulated by morphine. J. Pharmacol. Exp. Therap. 239, 88-93 (1986).
159. DeLander, G. E. & Hopkins, C. J. Interdependence of spinal adenosinergic, serotonergic and noradrenergic systems mediating antinociception. Neuropharmacology 26, 1791-1794 (1987).
160. 1 receptors in human brain regions. Neurosci. Lett. 297, 211-215 (2001).
161. Gurden, M. F. et al. Functional characterisation of three adenosine receptor types. Br. J. Pharmacol. 109, 693-698 (1993).
162. 1 receptor agonists measured using functional and radioligand binding. Br. J. Pharmacol. 131, 34P (2000).
163. 1) receptor agonists inhibit trigeminovascular nociceptive transmission. Brain 125, 1392-1401 (2002).
164. 1 receptors mediate the presynaptic inhibition of calcitonin gene related peptide release by adenosine in the rat spinal cord. Eur. J. Pharmacol. 231, 139-142 (1993).
165. 1 receptor agonist on trigeminally evoked dural blood vessel dilation in the anaesthetized rat. Cephalalgia 22, 260-264 (2000).
166. Kaube, H., Katsarava, Z., Kaufer, T., Diener, H.-C. & Ellrich, J. A new method to increase the nociception specificity of the human blink reflex. Clin. Neurophysiol. 111, 413-416 (2000).
167. 1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects. Cephalalgia 23, 287-292 (2003).
168. 1 receptor activation: A novel approach towards the design of new anti-migraine compounds. Cephalalgia 21, 268-269 (2001).
169. Meunier, J., Mouledous, L. & Topham, C. M. The nociceptin (ORL1) receptor: Molecular cloning and functional architecture. Peptides 21, 893-900 (2000).
170. Reinscheid, R. K., Nothacker, H. & Civelli, O. The orphanin FQ/ nociceptin gene: Structure, tissue distribution of expression and functional implications obtained from knockout mice. Peptides 21, 901-906 (2000).
171. Mogil, J. S. & Pasternak, G. W. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol. Rev. 53, 381-415 (2001).
172. Reinscheid, R. K. et al. Orphanin FQ: A neuropeptide that activates an opioid-like G protein-coupled receptor. Science 270, 792-794 (1995).
173. Darland, T. & Grandy, D. K. The orphanin FQ system: An emerging target for the management of pain? Br. J. Anaesth. 81, 29-37 (1998).
174. Hou, M., Tajti, J., Uddman, R. & Edvinsson, L. Demonstration of nociceptin positive cells and opioid-receptor like-1 in human trigeminal ganglion. Cephalalgia 21, 402 (2001).
175. Williamson, D. J., Hargreaves, R. J., Hill, R. G. & Shepheard, S. L. Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia 17, 518-524 (1997).
176. 1 receptor ligand nociceptin/orphanin FQ (N/OFQ) inhibits neurogenic vasodilatation in the rat. Neuropharmacology 43, 991-998 (2002).
177. Okuda-Ashitaka, E. et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature 392, 286-289 (1998).
178. Okuda-Ashitaka, E. & Ito, S. Nocistatin: A novel neuropeptide encoded by the gene for the nociceptin/orphanin FQ precursor. Peptides 21, 1101-1109 (2000).
179. Caterina, M. J. et al. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 389, 816-824 (1997).
180. Joo, F., Szolcsanyi, J. & Jancso-Gabor, A. Mitochondrial alterations in the spinal ganglion cells of the rat accompanying the long-lasting sensory disturbance induced by capsaicin. Life Sci. 8, 621-626 (1969).
181. Guo, A., Vulchanova, L., Wang, J., Li, X. & Elde, R. Immunocytochemical localization of the vanilloid receptor 1 (VR1): Relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur. J. Neurosci. 11, 946-958 (1999).
182. Ichikawa, H. & Sugimoto, T. VR1-immunoreactive primary sensory neurons in the rat trigeminal ganglion. Brain Res. 890, 184-188 (2001).
183. Hou, M., Uddman, R., Tajti, J., Kanje, M. & Edvinsson, L. Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci. Lett. 330, 223-226 (2002).
184. Akerman, S., Kaube, H. & Goadsby, P. J. Vanilloid type 1 receptor (VR1) evoked CGRP release plays a minor role in causing dural vessel dilation via the trigeminovascular system. Br. J. Pharmacol. 140, 718-724 (2003).
185. 1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 36, 525-533 (1997).
186. Williamson, D. J., Shepheard, S. L., Hill, R. G. & Hargreaves, R. J. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. 328, 61-64 (1997).
187. Matsuda, L. A., Lolait, S. J., Brownstein, M. J., Young, A. C. & Bonner, T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561-564 (1990).
188. Hoehe, M. R. et al. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol. 3, 880-885 (1991).
189. Devane, W. A. et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 1946-1949 (1992).
190. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 61-65 (1993).
191. Dewey, W. L. Cannabinoid pharmacology. Pharmacol. Rev. 38, 151-178 (1986).
192. Smith, P. B. et al. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270, 219-227 (1994).
193. Adams, I. B., Compton, D. R. & Martin, B. R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284, 1209-1217 (1998).
194. Crawley, J. N. et al. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol. Biochem. Behav 46, 967-972 (1993).
195. Akerman, S., Kaube, H. & Goadsby, P. J. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J. Pharmacol. Exp. Ther. 309, 56-63 (2004).
196. Zygmunt, P. M. et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457 (1999).
197. Akerman, S., Kaube, H. & Goadsby, P. J. Anandamide shows both cannabinoid and vanilloid properties in an in vivo model of trigeminovascular mediated headpain. Cephalalgia 23, 646 (2003).
198. Sakurai, T. et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 696-697 (1998).
199. de Lecea, L. et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl Acad. Sci. USA 95, 322-327 (1998).
200. Trivedi, P., Yu, H., MacNeil, D. J., Van der Ploeg, L. H. & Guan, X. M. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett. 436, 71-75 (1998).
201. Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015 (1998).
202. Marcus, J. N. et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J. Comp. Neurol. 435, 6-25 (2001).
203. Date, Y. et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc. Natl Acad. Sci. USA 96, 748-753 (1999),
204. Nambu, T. et al. Distribution of orexin neurons in the adult. rat brain. Brain Res. 827, 243-260 (1999).
205. Smart, D. & Jerman, J. The physiology and pharmacology of the orexins. Pharmacol. Ther. 94, 51 (2002).
206. van den Pol, A. N., Gao, X. B., Obrietan, K., Kilduff, T. S. & Belousov, A. B. Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J. Neurosci. 18, 7962-7971 (1998).
207. Siegel, J. M. Narcolepsy: A key role for hypocretins (orexins). Cell 98, 409-412 (1999).
208. Bingham, S. et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92, 81-90 (2001).
209. Yamamoto, T., Nozaki-Taguchi, N. & Chiba, T. Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test. Br. J. Pharmacol. 137, 170-176 (2002).
210. Grudt, T. J., van den Pol, A. N. & Perl, E. R. Hypocretin-2 (orexin-B) modulation of superficial dorsal horn activity in rat. J. Physiol. 538, 517-525 (2002).
211. Benjamin, L. et al. Hypothalamic activation after stimulation of the superior sagittal sinus in the cat: A Fos study. Neurobiol. Dis. 16, 500-505 (2004).
212. Bartsch, T., Levy, M. J., Knight, Y. E. & Goadsby, P. J. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 109, 367-378 (2004).
213. Hagan, J. J. et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl Acad. Sci. USA 96, 10911-10916 (1999).
214. Soffin, E. M. et al. SB-334867-A antagonises orexin mediated excitation in the locus coeruleus. Neuropharmacology 42, 127-133 (2002).
215. Thomsen, L. L. & Olesen, J. Nitric oxide in primary headaches. Curr. Opin. Neurol. 14, 315-321 (2001).
216. Thomsen, L. L. & Olesen, J. A pivotal role of nitric oxide in migraine pain. Ann. NY Acad. Sci. 835, 363-372 (1997).
217. Olesen, J., Thomsen, L. L., Lassen, L. H. & Olesen, I. J. The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia 15, 94-100 (1995).
218. Iversen, H. K., Olesen, J. & Tfelt-Hansen, P. Intravenous nitroglycerin as an experimental headache model. Basic characteristics. Pain 38, 17-24 (1989)
219. Giffin, N. J. et al. Premonitory symptoms in migraine: An electronic diary study. Neurology 60, 935-940 (2003).
220. Kruuse, C., Thomsen. L. L., Birk, S. & Olesen, J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 126, 241-247 (2003).
221. Reuter, U. et al. Delayed inflammation in rat meninges: Implications for migraine pathophysiology. Brain 124, 2490-2502 (2001).
222. Hoskin, K. L., Bulmer, D. C. E. & Goadsby, P. J. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci. Lett. 266, 173-176 (1999).
223. Lipton, R. B., Diamond, S., Reed, M., Diamond, M. L. & Stewart, W. F. Migraine diagnosis and treatment: Results from the American Migraine Study II. Headache 41, 638-645 (2001).
224. Matharu, M. S. et al. Central neuromodulation in chronic migraine patients with suboccipital stimulators: A PET study. Brain 127, 220-230 (2004).